AI-Pharma companies are 100 times as complex as FinTech companies. Methodologies used to assess them should be 100 times as rigorous, writes Margaretta Colangelo.
Dmitry Kaminskiy
Advertisement
Dmitry Kaminskiy is General Partner, Deep Knowledge Ventures
Articles by Dmitry Kaminskiy
Advertisement
Latest Updated Articles
Specialized Metrics to Properly Assess AI-Pharma StartupsApril 18th 2019
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Wegovy HD Injectable Under Accelerated Approval
2
TrumpRx Selling Medicines at Higher Prices Than Other Countries: Report
3
What Are the ‘Last Mile Issues’ Impacting Pharma?
4
Pharma M&A Roundup: Novartis to Acquire Pan-Mutant-Selective PI3Kα Inhibitor from Synnovation Therapeutics, Collegium to Acquire Azstarys from Corium Therapeutics
5